Английская Википедия:Helen Walden

Материал из Онлайн справочника
Версия от 10:00, 20 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{short description|English structural biologist}} {{Use dmy dates|date=April 2022}} {{Infobox scientist | name = Helen Walden | image = Helen Walden.jpg | image_size = | alt = Colour photograph of Helen Walden | caption = Helen Walden | birth_name = | birth_date = | birth_place = | death_date = | d...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Infobox scientist

Helen Walden Шаблон:Post-nominals is an English structural biologist who received the Colworth medal from the Biochemical Society in 2015.[1][2] She was awarded European Molecular Biology Organization (EMBO) membership in 2022. She is a Professor of Structural Biology at the University of Glasgow and has made significant contributions to the Ubiquitination field.[3]

Education and academic career

Helen Walden studied for a BSc in Biochemistry at the University of Bath. She moved to the University of St Andrews and was awarded a PhD for investigating the structural basis of protein hyperthermostability. After a postdoctoral fellowship at St Jude's Children's Research Hospital, Walden moved to London to set up a lab at the Cancer Research UK London Research Institute (and now part of the Francis Crick Institute). After tenure, Walden moved to the MRC-Phosphorylation and Ubiquitylation Unit at the University of Dundee where in 2016 she was promoted to professor.[4] In 2017, Walden relocated her lab to the University of Glasgow as Professor of Structural Biology.[3]

Research interests

At St Jude's Children's Research Hospital, Helen Walden developed her interest in the mechanisms of ubiquitination, solving the structure of the E1 for Nedd8.[5][6] In London, Walden studied the specificity and regulation of E3 ubiquitin ligases.[7][8] In recent years Walden has studied the mechanism and disease association of E2-conjugating enzymes.[9] Walden has investigated the role of Parkin in Parkinson's disease.[10][11] Her study of the Fanconi Anemia pathway has allowed Walden to begin developing small molecules to target the pathway.[12]

Professional associations and awards

References

Шаблон:Reflist

Шаблон:Authority control